WO1987003598A1 - Novel bisphosphonic derivatives, a method for their production and a pharmaceutical composition - Google Patents
Novel bisphosphonic derivatives, a method for their production and a pharmaceutical composition Download PDFInfo
- Publication number
- WO1987003598A1 WO1987003598A1 PCT/DK1986/000132 DK8600132W WO8703598A1 WO 1987003598 A1 WO1987003598 A1 WO 1987003598A1 DK 8600132 W DK8600132 W DK 8600132W WO 8703598 A1 WO8703598 A1 WO 8703598A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- methyl
- thiomorpholinylmethylene
- formyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 85
- 239000000203 mixture Substances 0.000 claims abstract description 43
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 150000002148 esters Chemical class 0.000 claims abstract description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 125000002723 alicyclic group Chemical group 0.000 claims abstract description 3
- 125000003118 aryl group Chemical group 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 3
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract 2
- 229930195733 hydrocarbon Natural products 0.000 claims abstract 2
- -1 hydrocarbon radical Chemical class 0.000 claims description 31
- 239000002253 acid Substances 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 claims description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 claims description 3
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 2
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims description 2
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims description 2
- XQXBTDLLYOTEID-UHFFFAOYSA-N [(2-methylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CC1CN(C(P(O)(O)=O)P(O)(O)=O)CCS1 XQXBTDLLYOTEID-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 150000003973 alkyl amines Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 230000002917 arthritic effect Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 150000003939 benzylamines Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 2
- 229960004919 procaine Drugs 0.000 claims description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims 2
- 125000005846 1-(alkanoyloxy)ethyl group Chemical group 0.000 claims 1
- 125000005042 acyloxymethyl group Chemical group 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 9
- 208000006386 Bone Resorption Diseases 0.000 abstract description 5
- 230000024279 bone resorption Effects 0.000 abstract description 5
- 125000001931 aliphatic group Chemical group 0.000 abstract description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 abstract description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 abstract description 3
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 235000013350 formula milk Nutrition 0.000 description 20
- HEMHJVSKTPXQMS-DYCDLGHISA-M Sodium hydroxide-d Chemical compound [Na+].[2H][O-] HEMHJVSKTPXQMS-DYCDLGHISA-M 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 229940122361 Bisphosphonate Drugs 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- JYMQQKIMCZOSMX-UHFFFAOYSA-N thiomorpholine-4-carbaldehyde Chemical compound O=CN1CCSCC1 JYMQQKIMCZOSMX-UHFFFAOYSA-N 0.000 description 6
- 238000009835 boiling Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 150000003462 sulfoxides Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 5
- 239000011710 vitamin D Substances 0.000 description 5
- 229940046008 vitamin d Drugs 0.000 description 5
- VBAFWEQEKVVPSO-UHFFFAOYSA-N 5,5-dimethylthiomorpholin-3-one Chemical compound CC1(C)CSCC(=O)N1 VBAFWEQEKVVPSO-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- GBFASMUCFQMOQT-UHFFFAOYSA-N 3-(2-methylpropyl)thiomorpholine-4-carbaldehyde Chemical compound CC(C)CC1CSCCN1C=O GBFASMUCFQMOQT-UHFFFAOYSA-N 0.000 description 3
- APKFOODJUNXXGQ-UHFFFAOYSA-N 3-tert-butylthiomorpholine Chemical compound CC(C)(C)C1CSCCN1 APKFOODJUNXXGQ-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- RZULBGMWKROXRP-UHFFFAOYSA-N [phosphono(thiomorpholin-4-yl)methyl]phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)N1CCSCC1 RZULBGMWKROXRP-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- FGRJGEWVJCCOJJ-UHFFFAOYSA-N 2,2-dimethylaziridine Chemical compound CC1(C)CN1 FGRJGEWVJCCOJJ-UHFFFAOYSA-N 0.000 description 2
- IHAASKVYTDOONZ-UHFFFAOYSA-N 2-butylthiomorpholin-3-one Chemical compound CCCCC1SCCNC1=O IHAASKVYTDOONZ-UHFFFAOYSA-N 0.000 description 2
- RVRJFUUCVPPSGQ-UHFFFAOYSA-N 2-butylthiomorpholine Chemical compound CCCCC1CNCCS1 RVRJFUUCVPPSGQ-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- PGXUNVXRKWWFNU-UHFFFAOYSA-N 3-tert-butylthiomorpholine-4-carbaldehyde Chemical compound CC(C)(C)C1CSCCN1C=O PGXUNVXRKWWFNU-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 0 CC(C)(C)C(C)(*)NN Chemical compound CC(C)(C)C(C)(*)NN 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- IRBUVBZWGHNOGM-UHFFFAOYSA-N [(3-phenylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)N1CCSCC1C1=CC=CC=C1 IRBUVBZWGHNOGM-UHFFFAOYSA-N 0.000 description 2
- FBZABVXUFGOLDA-UHFFFAOYSA-N [[3-(2-methylpropyl)thiomorpholin-4-yl]-phosphonomethyl]phosphonic acid Chemical compound CC(C)CC1CSCCN1C(P(O)(O)=O)P(O)(O)=O FBZABVXUFGOLDA-UHFFFAOYSA-N 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- KOUAQOCYMAENKN-UHFFFAOYSA-N ethyl 2-bromohexanoate Chemical compound CCCCC(Br)C(=O)OCC KOUAQOCYMAENKN-UHFFFAOYSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 208000030915 hypercalcemia disease Diseases 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- PELJISAVHGXLAL-UHFFFAOYSA-N iodomethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCI PELJISAVHGXLAL-UHFFFAOYSA-N 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000004452 microanalysis Methods 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RNLKVVKUFYPHQK-UHFFFAOYSA-N 1,4-thiazepan-3-one Chemical compound O=C1CSCCCN1 RNLKVVKUFYPHQK-UHFFFAOYSA-N 0.000 description 1
- SAIRZMWXVJEBMO-UHFFFAOYSA-N 1-bromo-3,3-dimethylbutan-2-one Chemical compound CC(C)(C)C(=O)CBr SAIRZMWXVJEBMO-UHFFFAOYSA-N 0.000 description 1
- IKWAFVHZRYXSCF-UHFFFAOYSA-N 2,2-dimethyl-3-phenylthiomorpholine-4-carbaldehyde Chemical compound CC1(C)SCCN(C=O)C1C1=CC=CC=C1 IKWAFVHZRYXSCF-UHFFFAOYSA-N 0.000 description 1
- RIAFLGSDZZYGNX-UHFFFAOYSA-N 2,2-dimethyl-3-propan-2-ylthiomorpholine-4-carbaldehyde Chemical compound CC(C)C1N(C=O)CCSC1(C)C RIAFLGSDZZYGNX-UHFFFAOYSA-N 0.000 description 1
- DIABDGGLDOYMGR-UHFFFAOYSA-N 2,2-dimethylthiomorpholine-4-carbaldehyde Chemical compound CC1(C)CN(C=O)CCS1 DIABDGGLDOYMGR-UHFFFAOYSA-N 0.000 description 1
- OSKSVESWLSCULX-UHFFFAOYSA-N 2,3-dimethylthiomorpholine Chemical compound CC1NCCSC1C OSKSVESWLSCULX-UHFFFAOYSA-N 0.000 description 1
- MNBQDDYTJUQZDE-UHFFFAOYSA-N 2,3-dimethylthiomorpholine-4-carbaldehyde Chemical compound CC1SCCN(C=O)C1C MNBQDDYTJUQZDE-UHFFFAOYSA-N 0.000 description 1
- PZXOGBYZFNUFQP-UHFFFAOYSA-N 2,5,5-trimethylthiomorpholine Chemical compound CC1CNC(C)(C)CS1 PZXOGBYZFNUFQP-UHFFFAOYSA-N 0.000 description 1
- SWVYJMUOFJFJPP-UHFFFAOYSA-N 2,5,5-trimethylthiomorpholine-4-carbaldehyde Chemical compound CC1CN(C=O)C(C)(C)CS1 SWVYJMUOFJFJPP-UHFFFAOYSA-N 0.000 description 1
- FHNSRKPKKIQKSW-UHFFFAOYSA-N 2,5-dimethylthiomorpholine-4-carbaldehyde Chemical compound CC1CN(C=O)C(C)CS1 FHNSRKPKKIQKSW-UHFFFAOYSA-N 0.000 description 1
- SYXPLTLMILVKGA-UHFFFAOYSA-N 2,6-dimethylthiomorpholine-4-carbaldehyde Chemical compound CC1CN(C=O)CC(C)S1 SYXPLTLMILVKGA-UHFFFAOYSA-N 0.000 description 1
- KGPBXEIHUOZHEH-UHFFFAOYSA-N 2-(2-methylpropyl)thiomorpholine-4-carbaldehyde Chemical compound CC(C)CC1CN(C=O)CCS1 KGPBXEIHUOZHEH-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 1
- HGBUYLHIOZGFCF-UHFFFAOYSA-N 2-butylthiomorpholine-4-carbaldehyde Chemical compound CCCCC1CN(C=O)CCS1 HGBUYLHIOZGFCF-UHFFFAOYSA-N 0.000 description 1
- SQVNITZYWXMWOG-UHFFFAOYSA-N 2-cyclohexyl-1-(2-methylquinolin-4-yl)-3-(1,3-thiazol-2-yl)guanidine Chemical compound C=12C=CC=CC2=NC(C)=CC=1NC(=NC1CCCCC1)NC1=NC=CS1 SQVNITZYWXMWOG-UHFFFAOYSA-N 0.000 description 1
- TUHNPFOWXIQLJM-UHFFFAOYSA-N 2-ethyl-3-methylthiomorpholine-4-carbaldehyde Chemical compound CCC1SCCN(C=O)C1C TUHNPFOWXIQLJM-UHFFFAOYSA-N 0.000 description 1
- OECUXOSVRRKICL-UHFFFAOYSA-N 2-ethyl-3-propylthiomorpholine-4-carbaldehyde Chemical compound CCCC1C(CC)SCCN1C=O OECUXOSVRRKICL-UHFFFAOYSA-N 0.000 description 1
- AXEDGKLMANSSBD-UHFFFAOYSA-N 2-ethylthiomorpholine-4-carbaldehyde Chemical compound CCC1CN(C=O)CCS1 AXEDGKLMANSSBD-UHFFFAOYSA-N 0.000 description 1
- IEXVIKXLKUOTJT-UHFFFAOYSA-N 2-methylthiomorpholine-4-carbaldehyde Chemical compound CC1CN(C=O)CCS1 IEXVIKXLKUOTJT-UHFFFAOYSA-N 0.000 description 1
- DYZPXIPRYAKKSD-UHFFFAOYSA-N 2-phenylthiomorpholine-4-carbaldehyde Chemical compound C1N(C=O)CCSC1C1=CC=CC=C1 DYZPXIPRYAKKSD-UHFFFAOYSA-N 0.000 description 1
- HHYNFVIFWWIJKM-UHFFFAOYSA-N 3,3-dimethylthiomorpholine-4-carbaldehyde Chemical compound CC1(C)CSCCN1C=O HHYNFVIFWWIJKM-UHFFFAOYSA-N 0.000 description 1
- FVVGBDJHKFVMNB-UHFFFAOYSA-N 3-(2-methylpropyl)-2-propan-2-ylthiomorpholine-4-carbaldehyde Chemical compound CC(C)CC1C(C(C)C)SCCN1C=O FVVGBDJHKFVMNB-UHFFFAOYSA-N 0.000 description 1
- UNPFQSJSUGZIPP-UHFFFAOYSA-N 3-benzyl-2-phenylthiomorpholine-4-carbaldehyde Chemical compound O=CN1CCSC(C=2C=CC=CC=2)C1CC1=CC=CC=C1 UNPFQSJSUGZIPP-UHFFFAOYSA-N 0.000 description 1
- PQIYSSSTRHVOBW-UHFFFAOYSA-N 3-bromopropan-1-amine;hydron;bromide Chemical compound Br.NCCCBr PQIYSSSTRHVOBW-UHFFFAOYSA-N 0.000 description 1
- KLKPXLXLTQXBGU-UHFFFAOYSA-N 3-butylthiomorpholine-4-carbaldehyde Chemical compound CCCCC1CSCCN1C=O KLKPXLXLTQXBGU-UHFFFAOYSA-N 0.000 description 1
- QGQQSSVTVQLSPH-UHFFFAOYSA-N 3-cyclohexylthiomorpholine-4-carbaldehyde;3-(3-methylbutyl)thiomorpholine-4-carbaldehyde Chemical compound CC(C)CCC1CSCCN1C=O.O=CN1CCSCC1C1CCCCC1 QGQQSSVTVQLSPH-UHFFFAOYSA-N 0.000 description 1
- QQAWLASMSQLQPM-UHFFFAOYSA-N 3-cyclopropylthiomorpholine-4-carbaldehyde Chemical compound O=CN1CCSCC1C1CC1 QQAWLASMSQLQPM-UHFFFAOYSA-N 0.000 description 1
- TWIDWPCHVDVSOS-UHFFFAOYSA-N 3-ethyl-2-methylthiomorpholine-4-carbaldehyde Chemical compound CCC1C(C)SCCN1C=O TWIDWPCHVDVSOS-UHFFFAOYSA-N 0.000 description 1
- DNMIVBANJOYANH-UHFFFAOYSA-N 3-ethylthiomorpholine-4-carbaldehyde Chemical compound CCC1CSCCN1C=O DNMIVBANJOYANH-UHFFFAOYSA-N 0.000 description 1
- VDIBJOCXIHQDHQ-UHFFFAOYSA-N 3-hexyl-2-pentylthiomorpholine-4-carbaldehyde Chemical compound CCCCCCC1C(CCCCC)SCCN1C=O VDIBJOCXIHQDHQ-UHFFFAOYSA-N 0.000 description 1
- TZYCEAITTMPLRY-UHFFFAOYSA-N 3-methyl-2-(2-methylpropyl)thiomorpholine-4-carbaldehyde Chemical compound CC(C)CC1SCCN(C=O)C1C TZYCEAITTMPLRY-UHFFFAOYSA-N 0.000 description 1
- MRQPBWBJNVLGMH-UHFFFAOYSA-N 3-methyl-2-propan-2-ylthiomorpholine-4-carbaldehyde Chemical compound CC(C)C1SCCN(C=O)C1C MRQPBWBJNVLGMH-UHFFFAOYSA-N 0.000 description 1
- QNXYWNNYQADWEB-UHFFFAOYSA-N 3-methylthiomorpholine-4-carbaldehyde Chemical compound CC1CSCCN1C=O QNXYWNNYQADWEB-UHFFFAOYSA-N 0.000 description 1
- WXGYFBQSKURIHV-UHFFFAOYSA-N 3-nonylthiomorpholine-4-carbaldehyde Chemical compound CCCCCCCCCC1CSCCN1C=O WXGYFBQSKURIHV-UHFFFAOYSA-N 0.000 description 1
- BNQAZDGFAAZLKK-UHFFFAOYSA-N 3-phenylthiomorpholine-4-carbaldehyde Chemical compound O=CN1CCSCC1C1=CC=CC=C1 BNQAZDGFAAZLKK-UHFFFAOYSA-N 0.000 description 1
- JVITXRSRPKDJMW-UHFFFAOYSA-N 3-propylthiomorpholine-4-carbaldehyde Chemical compound CCCC1CSCCN1C=O JVITXRSRPKDJMW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HZRXJDZDMIQKFL-UHFFFAOYSA-N 5-methyl-2-phenylthiomorpholine-4-carbaldehyde Chemical compound C1N(C=O)C(C)CSC1C1=CC=CC=C1 HZRXJDZDMIQKFL-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- YQCDBRIAVUEYFA-UHFFFAOYSA-N C(C)(C)C1N(CCSC1)C(P(O)(O)=O)P(O)(O)=O.C(CC)C1N(CCSC1)C(P(O)(O)=O)P(O)(O)=O Chemical compound C(C)(C)C1N(CCSC1)C(P(O)(O)=O)P(O)(O)=O.C(CC)C1N(CCSC1)C(P(O)(O)=O)P(O)(O)=O YQCDBRIAVUEYFA-UHFFFAOYSA-N 0.000 description 1
- PYFYERKDLPIUAD-UHFFFAOYSA-N C(CCCC)C1C(N(CCS1)C(P(O)(O)=O)P(O)(O)=O)CCCCCC.C1(=CC=CC=C1)C1C(N(CCS1)C(P(O)(O)=O)P(O)(O)=O)CC1=CC=CC=C1 Chemical compound C(CCCC)C1C(N(CCS1)C(P(O)(O)=O)P(O)(O)=O)CCCCCC.C1(=CC=CC=C1)C1C(N(CCS1)C(P(O)(O)=O)P(O)(O)=O)CC1=CC=CC=C1 PYFYERKDLPIUAD-UHFFFAOYSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
- LXXNWCFBZHKFPT-UHFFFAOYSA-N Ethyl 2-mercaptopropionate Chemical group CCOC(=O)C(C)S LXXNWCFBZHKFPT-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 241000820057 Ithone Species 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 125000000205 L-threonino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])[C@](C([H])([H])[H])([H])O[H] 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 206010044029 Tooth deposit Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- CTDQVUASXKLHGF-UHFFFAOYSA-N [(2,2-dimethyl-3-propan-2-ylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CC(C)C1N(C(P(O)(O)=O)P(O)(O)=O)CCSC1(C)C CTDQVUASXKLHGF-UHFFFAOYSA-N 0.000 description 1
- UDPJXBFABPMOGO-UHFFFAOYSA-N [(2,2-dimethylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CC1(C)CN(C(P(O)(O)=O)P(O)(O)=O)CCS1 UDPJXBFABPMOGO-UHFFFAOYSA-N 0.000 description 1
- HQAFIMHZOMPZQD-UHFFFAOYSA-N [(2,5-dimethylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CC1CN(C(P(O)(O)=O)P(O)(O)=O)C(C)CS1 HQAFIMHZOMPZQD-UHFFFAOYSA-N 0.000 description 1
- LOPKSWKTRVMTQJ-UHFFFAOYSA-N [(2,6-dimethylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CC1CN(C(P(O)(O)=O)P(O)(O)=O)CC(C)S1 LOPKSWKTRVMTQJ-UHFFFAOYSA-N 0.000 description 1
- XXAFXRGCZRMKDC-UHFFFAOYSA-N [(2-butylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CCCCC1CN(C(P(O)(O)=O)P(O)(O)=O)CCS1 XXAFXRGCZRMKDC-UHFFFAOYSA-N 0.000 description 1
- GKAXHXRIBJKFQB-UHFFFAOYSA-N [(2-ethyl-3-methylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CCC1SCCN(C(P(O)(O)=O)P(O)(O)=O)C1C GKAXHXRIBJKFQB-UHFFFAOYSA-N 0.000 description 1
- RNEGGQCDTOASNN-UHFFFAOYSA-N [(2-ethyl-3-propylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CCCC1C(CC)SCCN1C(P(O)(O)=O)P(O)(O)=O RNEGGQCDTOASNN-UHFFFAOYSA-N 0.000 description 1
- MXZOXPMRJGYIMH-UHFFFAOYSA-N [(2-ethylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CCC1CN(C(P(O)(O)=O)P(O)(O)=O)CCS1 MXZOXPMRJGYIMH-UHFFFAOYSA-N 0.000 description 1
- OIANZWACCFYREL-UHFFFAOYSA-N [(2-phenylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound C1N(C(P(O)(=O)O)P(O)(O)=O)CCSC1C1=CC=CC=C1 OIANZWACCFYREL-UHFFFAOYSA-N 0.000 description 1
- MLMDQEBOTKVJNP-UHFFFAOYSA-N [(3,3-dimethylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CC1(C)CSCCN1C(P(O)(O)=O)P(O)(O)=O MLMDQEBOTKVJNP-UHFFFAOYSA-N 0.000 description 1
- OZVJXTZENYHYAK-UHFFFAOYSA-N [(3-butylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CCCCC1CSCCN1C(P(O)(O)=O)P(O)(O)=O OZVJXTZENYHYAK-UHFFFAOYSA-N 0.000 description 1
- ZIFCDUXJZVKMAO-UHFFFAOYSA-N [(3-cyclohexylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)N1CCSCC1C1CCCCC1 ZIFCDUXJZVKMAO-UHFFFAOYSA-N 0.000 description 1
- SWFWQPZEAFZNPM-UHFFFAOYSA-N [(3-cyclopropylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)N1CCSCC1C1CC1 SWFWQPZEAFZNPM-UHFFFAOYSA-N 0.000 description 1
- KANAGHSCTAPDJX-UHFFFAOYSA-N [(3-ethyl-2-methylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CCC1C(C)SCCN1C(P(O)(O)=O)P(O)(O)=O KANAGHSCTAPDJX-UHFFFAOYSA-N 0.000 description 1
- HHUOGQCBRYKTEF-UHFFFAOYSA-N [(3-ethylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CCC1CSCCN1C(P(O)(O)=O)P(O)(O)=O HHUOGQCBRYKTEF-UHFFFAOYSA-N 0.000 description 1
- QUTSVRXXWHJUJH-UHFFFAOYSA-N [(3-methylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CC1CSCCN1C(P(O)(O)=O)P(O)(O)=O QUTSVRXXWHJUJH-UHFFFAOYSA-N 0.000 description 1
- AXDBKJXNONMSCM-UHFFFAOYSA-N [(3-nonylthiomorpholin-4-yl)-phosphonomethyl]phosphonic acid Chemical compound CCCCCCCCCC1CSCCN1C(P(O)(O)=O)P(O)(O)=O AXDBKJXNONMSCM-UHFFFAOYSA-N 0.000 description 1
- JZJNHPJBZWEHPD-UHFFFAOYSA-N [F].[Na] Chemical compound [F].[Na] JZJNHPJBZWEHPD-UHFFFAOYSA-N 0.000 description 1
- CZENFMYWJQUBQF-UHFFFAOYSA-N [[3-(2-methylpropyl)-2-propan-2-ylthiomorpholin-4-yl]-phosphonomethyl]phosphonic acid Chemical compound CC(C)CC1C(C(C)C)SCCN1C(P(O)(O)=O)P(O)(O)=O CZENFMYWJQUBQF-UHFFFAOYSA-N 0.000 description 1
- JUOXNPMVIMFFJI-UHFFFAOYSA-N [[3-(3-methylbutyl)thiomorpholin-4-yl]-phosphonomethyl]phosphonic acid Chemical compound CC(C)CCC1CSCCN1C(P(O)(O)=O)P(O)(O)=O JUOXNPMVIMFFJI-UHFFFAOYSA-N 0.000 description 1
- LVEMXVBMOMXEKQ-UHFFFAOYSA-N [phosphono-(2,5,5-trimethylthiomorpholin-4-yl)methyl]phosphonic acid Chemical compound CC1CN(C(P(O)(O)=O)P(O)(O)=O)C(C)(C)CS1 LVEMXVBMOMXEKQ-UHFFFAOYSA-N 0.000 description 1
- SZNUTEDJPBLFJC-UHFFFAOYSA-N [phosphono-(3-propan-2-ylthiomorpholin-4-yl)methyl]phosphonic acid Chemical compound CC(C)C1CSCCN1C(P(O)(O)=O)P(O)(O)=O SZNUTEDJPBLFJC-UHFFFAOYSA-N 0.000 description 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000010256 bone deposition Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- PVBRSNZAOAJRKO-UHFFFAOYSA-N ethyl 2-sulfanylacetate Chemical compound CCOC(=O)CS PVBRSNZAOAJRKO-UHFFFAOYSA-N 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000000121 hypercalcemic effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NZDJTVSTIFYISQ-UHFFFAOYSA-N iodomethyl acetate Chemical group CC(=O)OCI NZDJTVSTIFYISQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 description 1
- SNWKNPMDQONHKK-UHFFFAOYSA-N methyl 2-sulfanylpropanoate Chemical compound COC(=O)C(C)S SNWKNPMDQONHKK-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- CVVVRVRQWUMYNX-UHFFFAOYSA-N n,n-bis(prop-2-enyl)formamide Chemical compound C=CCN(C=O)CC=C CVVVRVRQWUMYNX-UHFFFAOYSA-N 0.000 description 1
- HVAAHUDGWQAAOJ-UHFFFAOYSA-N n-benzylethanamine Chemical compound CCNCC1=CC=CC=C1 HVAAHUDGWQAAOJ-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 229940090008 naprosyn Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- RQKYHDHLEMEVDR-UHFFFAOYSA-N oxo-bis(phenylmethoxy)phosphanium Chemical compound C=1C=CC=CC=1CO[P+](=O)OCC1=CC=CC=C1 RQKYHDHLEMEVDR-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- HXEIHZUIHQVYMN-UHFFFAOYSA-N sodium;dibenzyl phosphite Chemical compound [Na+].C=1C=CC=CC=1COP([O-])OCC1=CC=CC=C1 HXEIHZUIHQVYMN-UHFFFAOYSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000004886 thiomorpholines Chemical class 0.000 description 1
- 229950006828 timegadine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6544—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
Definitions
- Novel bisphosphonic derivatives a method for their production and a pharmaceutical composition.
- the present invention relates to hitherto unknown compounds useful in the human and veterinary therapy, to pharmaceutically acceptable salts and easily hydrolyzable esters thereof, to methods for producing said new compounds, to pharmaceutical compositions containing the new compounds, to dosage units of the compositions, and to methods of treat ⁇ ing patients using said compositions and dosage units.
- R..-R.... can be the same or different and stand for hydrogen, a straight or branched aliphatic or alicyclic C 1 ⁇ C 10 n y drocarDo ⁇ radical, an aryl or an ary1-C, -C. -alkyl radical; n is zero or one, and m is zero, one or two.
- R lagoon and R. when taken together can form a saturated aliphatic 5-, 6- or 7-membered ring which may be substituted ith one or more C,-C. -alkyl radicals.
- R -R_ - stand for hydrogen, C- -C 5 -alky1 , or phenyl .
- the invention comprises all possible stereoisomeric forms of compounds of formula I as well as mixtures thereof.
- the invention also relates to salts of the compounds of formula I which are acids and thus form salts with bases.
- alkali metal salts and alkaline earth metal salts such as lithium, sodium, potassium, magnesium, calcium salts
- suitable non-toxic amines such as lower alkylamines, e.g. triethylamine , lower alkan- olamines, e.g. diethanolamine or triethanolamine, procaine, 5 cycloalkylamines, e.g. dicyclohexylamine, benzylamines, e.g.
- esters of the present compounds are i ⁇ vivo eas ⁇ ily hydrolyzable .
- ester forming residues are alkanoyloxy ethyl of three to six carbon atoms, l-(alk- anoyloxy)ethyl of four to seven carbon atoms, 1-methyl-l- (alkanoyloxy)ethyl of five to eight carbon atoms, alkoxy-
- the normal bones are living tissues undergoing con ⁇ stant resorption and r ⁇ deposition of calcium, with the net effect of aintenance of a constant mineral balance.
- bone turnover In normal grow-, ing bones, the mineral deposition exceeds the mineral re ⁇ sorption, whereas in certain pathological conditions, bone resorption exceeds bone deposition resulting in e.g. hyper- calcemia, for instance due to malignancy or primary hyper- 0 parathyroidism, or in osteoporosis. In other pathological conditions the calcium deposition may take place in undesir ⁇ able amounts and areas leading to e.g. osteoarthritis , rheu ⁇ matoid arthritis, kidney or bladder stones, atherosclerosis, and Paget's disease which is a combination of an abnormal
- the compounds of the present invention like known bisphosphonates (e.g. 1-hydroxyethy1idene-1 ,1-bisphosphonic acid (etidronate) and 3-amino-1-hydroxypropylidene-1 , 1-bisphosphonic acid (APD)) reduce bone resorption as shown by their inhibition of the urinary excretion of hydroxyproline , but in contrast to these known compounds which also inhibit bone alkaline phosphatase, the new compounds of this invention surpris ⁇ ingly stimulate bone alkaline phosphatase, indicating a stimulation of the bone forming cells - the osteoblasts - and a substantial increase in bone mass is actually observed during treatment with the present compounds.
- known bisphosphonates e.g. 1-hydroxyethy1idene-1 ,1-bisphosphonic acid (etidronate) and 3-amino-1-hydroxypropylidene-1 , 1-bisphosphonic acid (APD)
- etidronate 1-hydroxyethy1idene-1
- R--R,- and m have the meanings mentioned above.
- the compounds of formula II are either known or may be prepared in analogy with the known compounds. They are transformed into acid amide chlorides of formula III by treatment with e.g. phosgene or oxalyl chloride
- R--R,, and m have the meanings defined above and R,_ is a C.-C. -alkyl radical, preferably methyl or ethyl, or a benzyl or a substituted benzyl radical.
- esters may also be cleaved by an alternative method described in Jour. f. prakt. Chemie 320 , 344 (1978). Treatment with bromotrimethylsilane at room temperature or moderately elevated temperature leads to a tetra-tri- methylsilyl ester which is easily cleaved with water or alcohol to yield the free acid of formula I.
- Easily hydrolyzable esters of the compounds of formula I may be prepared by reacting a salt, e.g. a silver salt or a quaternary ammonium salt, of a compound of formula I with a reactive halide corresponding to the desired ester.
- a salt e.g. a silver salt or a quaternary ammonium salt
- Tetra-esters may be cleaved by reaction with an iodide, e.g. sodium iodide, to form di-esters of the com- pounds of formula I.
- an iodide e.g. sodium iodide
- the present compounds are as mentioned above in ⁇ tended for use in pharmaceutical compositions which are useful in the treatment of osteoporosis, rheumatoid ar ⁇ thritis and other arthritic disorders, atherosclerosis, hypercalcemia due to malignancies or primary hyperpara- thyroidism, Paget's disease, and other conditions with an abnormal calcium balance.
- the present compounds may also be used in tooth ⁇ pastes in order to prevent calcium deposition in the form of dental calculus or in order to protect against calcium resorption due to acid dissolution.
- a suitable dose of a compound of formula I for a mammal suffering from ' e.g. a hypercalcemic condition as defined hereinbefore is 0.001 to 25 mg per kilogram body ⁇ weight, the most preferred dosage being 0.002 to 10 mg/kg of mammal bodyweight, for example 0.005 to 5 mg/kg; admini ⁇ stered once or more times daily.
- a suitable dose of a compound of for mula (I) is 0.001 to 10 mg per kilogram bodyweight, the most preferred dosage being 0.002 to 5 mg/kg of mammal bodyweight.
- an active ingredient comprises from 0.1? ⁇ to 99.9.0 by weight of the formulation.
- dosage units of a formulation contain between 0.1 mg and 1 g of the active ingredient.
- the active ingredient preferably comprises from 1% to 2% by weight of the formulation but the active ingredient may comprise as much as 10% w/w.
- dosage unit is meant a unitary) i.e. a single dose which is capable of being administered to a patient, and which may be readily handled and packed, re- maining as a physically stable unit dose comprising either the active material as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers.
- the formulations both for veterinary and for human medical use, of the present invention comprise an active ingredient in association with a pharmaceutically accept ⁇ able carrier ' and optionally other therapeutic ingredient(s).
- the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof.
- the formulations include those in a form suitable for oral, rectal, parenteral (including subcutaneous, intra ⁇ muscular and intravenous), or topical administration.
- the formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
- Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion.
- the active ingredient may also be in the form of bolus, electuary or paste.
- Formulations for rectal administration may be in the form of a suppository incorporating the active ingre- 5 histone, or in the form of an enema.
- Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active ingredient which is preferably isoto ⁇ ic with the - ⁇ - blood of the recipient.
- Formulations suitable for topical administration include liquid or semi-liquid preparations such as lini ⁇ ments, lotions, applications; oil-in-water or water-in-oil emulsions such as creams, ointments or pastes, including 15 tooth-pastes; or solutions or suspensions such as drops.
- the formulations of this invention may include one or more additional ingredients such as diluents, buffers, flavour ⁇ ing agents, binders, surface active agents, thickeners, 0 lubricants, preservatives, e.g. methylhydroxybenzoate (in ⁇ cluding anti-oxidants) , emulsifying agents and the like.
- additional ingredients such as diluents, buffers, flavour ⁇ ing agents, binders, surface active agents, thickeners, 0 lubricants, preservatives, e.g. methylhydroxybenzoate (in ⁇ cluding anti-oxidants) , emulsifying agents and the like.
- compositions may further contain other thera-Guinically active compounds usually applied in the treat ⁇ ment of the above mentioned pathological ' conditions , for 5 instance vitamin D floss and D, and hydroxylated derivatives, e.g. l ⁇ -hydroxy-vitamin D,, l ⁇ -hydroxy-vitamin D ⁇ , l ⁇ .,25- -dihydroxy-vitamin D,, l ⁇ , 25-dihydroxy-vitamin D combat , calci- tonin (human, porcine or salmon), mitramycin, sodium fluor ⁇ ide, estrogens, and non-steroid antiinflammatory drugs, 0 e.g. acetylsalicylic acid, indomethacin , naprosyn, and timegadine .
- other thera-Guilated derivatives e.g. l ⁇ -hydroxy-vitamin D, l ⁇ -hydroxy-vitamin D ⁇ , l ⁇ .,25- -dihydroxy-vitamin D,, l ⁇ , 25-
- the present compounds are administered to a patient suffering from one of the above mentioned pathological conditions in a daily dose 5 (for adults) from 0.07 mg to 1750 mg, preferably from 0.15 - 1000 mg, and in the veterinary practice correspondingly in daily doses from 0.001 to 25 mg/kg bodyweight.
- This compound was prepared as described in Prepara- tion 2 by substituting 2 , 5 , 5-tri ethy1-3-thiomorpholinone for 5,5-dimethyl-3-thiomorpholinone. Boiling point: 76 - 77°C/15 mmHg.
- N-Formyl-3,3-dimethyl-thiomorpholine B.p.: 155-156°C/15mmHg
- N-Formyl-2,5,5-trimethyl-thiomorpholine B.p. : 154-155°C/15 mmHg
- N-Formyl-2-(1-butyl)-thiomorpholine B.p. : 160-162°C/15 mmHg
- N-Formyl-2-phenyl-thiomorpholine B . .p. : 148-150 ⁇ C/l mmHg
- N-Formyl-2-isobutyl-3-methyl-thiomorpholine B.p. : 115-116°C/1 mmHg
- N-Formy l - perhydro- l , 4-benz oth iaz i ne
- N-Formyl-2-isobutyl-thiomorpholine B.p. : 150-155°C/15 mmHg
- N-Formyl-2,5-dimethyl-thiomorpholine B.p. : 142-143°C/15 mmHg
- This compound was prepared as described in Prepara ⁇ tion 10 by using bromomethyl tert-butyl ketone instead of ⁇ -bromo-diethyl ketone and by omitting the treatment with chloral.
- the title compound was distilled in vacuo, b.p. : 73-74°C/l mmHg.
- This compound was prepared by following the proce- dure of Preparation 19, but substituting ethyl 2-mercapto- propionate for ethyl thiogiycolate .
- 2-Methy1-tetrahydro- -l,4-thiaz ⁇ pin-3-one with m.p. 192-193°C was isolated as an intermediate.
- the title compound was a colourless oil with b.p. 104-105°C/1 mmHg.
- Oxalyl chloride (16.6 ml) was added dropwise at 0°C to a stirred solution of N-formyl-thiomorpholine (26.2 g) in methylene chloride (200 ml). The mixture was stirred at room temperature until the gas evolution ceased (about 5 hours later). Triethyl phosphite (66 ml) was then added during 1.5 hours at room temperature. Unreacted triethyl phosphite was removed i_n_ vacuo , and the residue was refluxed with 20 °a' hydrochloric acid (150 ml) for 3 hours. The mixture was evaporated to dryness in_ vacuo , and the residue was stirred with acetone. The crystalline product was filtered and recrystallized from water. M.p.: >250°C (dec). Microanalysis :
- Example 2 By following the procedure described in Example 1 and substituting the appropriate N-formyl-derivatives de ⁇ scribed in Preparations 8, 9, 10, 11 and 12 for N-formyl- -thiomorpholine, the following compounds were prepared:
- Oxalyl chloride (0.85 ml) was added dropwise at -10°C to a stirred solution of N-formyl-thiomorpholine (1.31 g) in tetrahydrofuran (10 ml), arid the mixture was stirred at -10°C for 1 hour.
- Example 6 The procedure of Example 1 is repeated, except that N-formyl-thiomorpholine is replaced by the appropriate N- -formyl derivatives described in Preparation 13. This af ⁇ fords :
- Example 8 The procedure of Example 7 was repeated, except that N-formyl-3-isobuty1-thiomorpholi ⁇ e was replaced by the appropriate N-formyl-derivative described in Preparation 13, 17 and 18. In this way the following compounds were prepared
- This compound was prepared from tetra-acetoxym ⁇ thy1 ( -thiomorpholinylmethyl ⁇ ne )-bisphosphonate by following the procedure of Example 14.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Novel compounds of formula (I), in which R1?-R11? can be the same or different and stand for hydrogen, a straight or branched aliphatic or alicyclic C1?-C10? hydrocarbon radical, an aryl or an aryl-C1?-C4?-alkyl radical; n is zero or one, and m is zero, one or two; or R2? and R4? when taken together form a saturated aliphatic 5-, 6- or 7-membered ring which may be substituted with one or more C1?-C4?-alkyl radicals; and pharmaceutically acceptable salts and easily hydrolyzable esters thereof, methods for producing said new compounds, pharmaceutical compositions containing the new compounds, dosage units of the compositions, and methods of treating patients using said compositions and dosage units. The present compounds are valuable in the human and veterinary practice by reducing bone resorption and surprisingly also stimulating bone alkaline phosphatase. A substantial increase in bone mass is actually observed during treatment with the present compounds.
Description
Novel bisphosphonic derivatives, a method for their production and a pharmaceutical composition.
The present invention relates to hitherto unknown compounds useful in the human and veterinary therapy, to pharmaceutically acceptable salts and easily hydrolyzable esters thereof, to methods for producing said new compounds, to pharmaceutical compositions containing the new compounds, to dosage units of the compositions, and to methods of treat¬ ing patients using said compositions and dosage units.
The present compounds have the formula I
in which R..-R.... can be the same or different and stand for hydrogen, a straight or branched aliphatic or alicyclic C1~C10 nydrocarDoπ radical, an aryl or an ary1-C, -C. -alkyl radical; n is zero or one, and m is zero, one or two.
In addition R„ and R. when taken together can form a saturated aliphatic 5-, 6- or 7-membered ring which may be substituted ith one or more C,-C. -alkyl radicals.
In particular, R -R_ - stand for hydrogen, C- -C5-alky1 , or phenyl .
The invention comprises all possible stereoisomeric forms of compounds of formula I as well as mixtures thereof.
As stated above, the invention also relates to salts of the compounds of formula I which are acids and thus form salts with bases. As examples of salts formed with pharma¬ ceutically acceptable, non-toxic ' bases , mention may be made of alkali metal salts and alkaline earth metal salts, such
as lithium, sodium, potassium, magnesium, calcium salts, as well as salts with ammonia and suitable non-toxic amines, such as lower alkylamines, e.g. triethylamine , lower alkan- olamines, e.g. diethanolamine or triethanolamine, procaine, 5 cycloalkylamines, e.g. dicyclohexylamine, benzylamines, e.g. N-methylbenzylamine, N-ethylbenzylamine , N-benzyl-β-phen- ethyla'mine, N,N ' -dibenzylethylenediamine or dibenzylamine , and heterocyclic amines, e.g. morpholine, N-ethylpiperidine and the like.
10 The esters of the present compounds are i ~ vivo eas¬ ily hydrolyzable . Examples of such ester forming residues are alkanoyloxy ethyl of three to six carbon atoms, l-(alk- anoyloxy)ethyl of four to seven carbon atoms, 1-methyl-l- (alkanoyloxy)ethyl of five to eight carbon atoms, alkoxy-
15 carbonyloxymethyl of three to six carbon atoms, l-(alkoxy- carbonyloxy )ethyl of four to seven carbon atoms, 1-methyl-l- -(alkoxycarbonyloxy )ethyl of five to eight carbon atoms, 3- -phthalidyl, 4-crotonolactonyl , y*-butyrolacton-4-yl , (2-oxo- -1 ,3-dioxόlen-4-yl )methyl , (5-methyl-2-oxo-l, -dioxolen-4-
20 -yl)methyl, and (5-phenyl-2-oxo-l ,3-dioxolen-4-yl)methyl as well as dialkylaminoalkyl , acetonyl, and methoxymethyl .
The normal bones are living tissues undergoing con¬ stant resorption and rεdeposition of calcium, with the net effect of aintenance of a constant mineral balance. The dual
25 process is commonly called "bone turnover". In normal grow-, ing bones, the mineral deposition exceeds the mineral re¬ sorption, whereas in certain pathological conditions, bone resorption exceeds bone deposition resulting in e.g. hyper- calcemia, for instance due to malignancy or primary hyper- 0 parathyroidism, or in osteoporosis. In other pathological conditions the calcium deposition may take place in undesir¬ able amounts and areas leading to e.g. osteoarthritis , rheu¬ matoid arthritis, kidney or bladder stones, atherosclerosis, and Paget's disease which is a combination of an abnormal
^ high bone resorption followed by an abnormal calcium depo¬ sition.
Most of the currently available therapeutic agents
for the treatment of osteoporosis, e.g. estrogens and cal- citonin, act by reducing bone resorption in the osteoporotic patient. Since bone fracture is a severe problem in osteopo¬ rosis, the ideal therapeutic agent should be able to in¬ crease bone mass to a level which exceeds the fracture thres¬ hold.
Experiments in rats have shown that the compounds of the present invention like known bisphosphonates (e.g. 1-hydroxyethy1idene-1 ,1-bisphosphonic acid (etidronate) and 3-amino-1-hydroxypropylidene-1 , 1-bisphosphonic acid (APD)) reduce bone resorption as shown by their inhibition of the urinary excretion of hydroxyproline , but in contrast to these known compounds which also inhibit bone alkaline phosphatase, the new compounds of this invention surpris¬ ingly stimulate bone alkaline phosphatase, indicating a stimulation of the bone forming cells - the osteoblasts - and a substantial increase in bone mass is actually observed during treatment with the present compounds.''
The compounds of the present invention (n = 0) may be prepared from a compound of formula II
where R--R,- and m have the meanings mentioned above. The compounds of formula II are either known or may be prepared in analogy with the known compounds. They are transformed into acid amide chlorides of formula III by treatment with e.g. phosgene or oxalyl chloride
(R,-R,, and m as defined above). Reaction of compounds of formula III with trialkyl- phosphites leads to tetraalkyl esters of formula IV
where R--R,, and m have the meanings defined above and R,_ is a C.-C. -alkyl radical, preferably methyl or ethyl, or a benzyl or a substituted benzyl radical.
Cleavage of the esters of formula IV by hydrolysis, e.g. with boiling hydrochloric acid, or by hydrogenolysis , leads to the compounds of formula I (n = 0).
The esters may also be cleaved by an alternative method described in Jour. f. prakt. Chemie 320 , 344 (1978). Treatment with bromotrimethylsilane at room temperature or moderately elevated temperature leads to a tetra-tri- methylsilyl ester which is easily cleaved with water or alcohol to yield the free acid of formula I.
Alternatively, compounds of formula I (n = 0) may be prepared by reacting compounds of formula II with phos¬ phorous acid and phosphorus trichloride followed by hydro¬ lysis of the reaction mixture.
Compounds of formula I in which n = 1 may be prepared by oxidation of compounds of formula I or IV (n = 0) with
the well known reagents for the preparation of sulfoxides from sulfides, e.g. 3-chloroperbenzoic acid or hydrogen peroxide, optionally followed by ester cleavage.
Easily hydrolyzable esters of the compounds of formula I may be prepared by reacting a salt, e.g. a silver salt or a quaternary ammonium salt, of a compound of formula I with a reactive halide corresponding to the desired ester.
Tetra-esters may be cleaved by reaction with an iodide, e.g. sodium iodide, to form di-esters of the com- pounds of formula I.
The present compounds are as mentioned above in¬ tended for use in pharmaceutical compositions which are useful in the treatment of osteoporosis, rheumatoid ar¬ thritis and other arthritic disorders, atherosclerosis, hypercalcemia due to malignancies or primary hyperpara- thyroidism, Paget's disease, and other conditions with an abnormal calcium balance.
The present compounds may also be used in tooth¬ pastes in order to prevent calcium deposition in the form of dental calculus or in order to protect against calcium resorption due to acid dissolution.
The amount required of a compound of formula I (here¬ inafter referred to as the active ingredient) for thera¬ peutic effect will, of course, vary both with the, particular compound, the route of administration and the mammal under treatment. A suitable dose of a compound of formula I for a mammal suffering from' e.g. a hypercalcemic condition as defined hereinbefore is 0.001 to 25 mg per kilogram body¬ weight, the most preferred dosage being 0.002 to 10 mg/kg of mammal bodyweight, for example 0.005 to 5 mg/kg; admini¬ stered once or more times daily.
In the case of the profylactic treatment of e.g. post- memopausal osteoporosis, a suitable dose of a compound of for mula (I) is 0.001 to 10 mg per kilogram bodyweight, the most preferred dosage being 0.002 to 5 mg/kg of mammal bodyweight. While it is possible for an active ingredient to be administered alone as the pure compound, it is prefer¬ able to present it as a pharmaceutical formulation. Conve¬ niently, the active ingredient comprises from 0.1?≤ to 99.9.0
by weight of the formulation. Conveniently., dosage units of a formulation contain between 0.1 mg and 1 g of the active ingredient. For topical administration, the active ingredient preferably comprises from 1% to 2% by weight of the formulation but the active ingredient may comprise as much as 10% w/w.
By the term "dosage unit" is meant a unitary) i.e. a single dose which is capable of being administered to a patient, and which may be readily handled and packed, re- maining as a physically stable unit dose comprising either the active material as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers.
The formulations, both for veterinary and for human medical use, of the present invention comprise an active ingredient in association with a pharmaceutically accept¬ able carrier' and optionally other therapeutic ingredient(s). The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof. The formulations include those in a form suitable for oral, rectal, parenteral (including subcutaneous, intra¬ muscular and intravenous), or topical administration.
The formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil
emulsion. The active ingredient may also be in the form of bolus, electuary or paste.
Formulations for rectal administration may be in the form of a suppository incorporating the active ingre- 5 dient and a carrier such as cocoa butter, or in the form of an enema.
Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active ingredient which is preferably isotoπic with the -■ - blood of the recipient.
Formulations suitable for topical administration include liquid or semi-liquid preparations such as lini¬ ments, lotions, applications; oil-in-water or water-in-oil emulsions such as creams, ointments or pastes, including 15 tooth-pastes; or solutions or suspensions such as drops.
In addition to the aforementioned ingredients, the formulations of this invention may include one or more additional ingredients such as diluents, buffers, flavour¬ ing agents, binders, surface active agents, thickeners, 0 lubricants, preservatives, e.g. methylhydroxybenzoate (in¬ cluding anti-oxidants) , emulsifying agents and the like.
The compositions may further contain other thera- peutically active compounds usually applied in the treat¬ ment of the above mentioned pathological ' conditions , for 5 instance vitamin D„ and D, and hydroxylated derivatives, e.g. lα-hydroxy-vitamin D,, lα-hydroxy-vitamin D~ , lα.,25- -dihydroxy-vitamin D,, lα, 25-dihydroxy-vitamin D„ , calci- tonin (human, porcine or salmon), mitramycin, sodium fluor¬ ide, estrogens, and non-steroid antiinflammatory drugs, 0 e.g. acetylsalicylic acid, indomethacin , naprosyn, and timegadine .
According to the invention, the present compounds are administered to a patient suffering from one of the above mentioned pathological conditions in a daily dose 5 (for adults) from 0.07 mg to 1750 mg, preferably from 0.15 - 1000 mg, and in the veterinary practice correspondingly in daily doses from 0.001 to 25 mg/kg bodyweight.
The invention will now be further described in the following non-limiting Preparations and Examples:
Preparation 1 5,5-Dimethyl-3-thiomorpholinone
2 , 2-Dimethylaziridine (35.5 g) was added dropwise with stirring at 100°C to methyl mercaptoacetate (53 g) during 1.5 hours. After a further 2 hours at 100QC, the mixture -was cooled and crystallized from ethyl acetate. Melting point: 151 - 152°C.
Preparation 2 ,3-Dimethyl-thiomorpholine
5 , 5-Dimethyl-3-thiomorpholinone (50 g) was added in portions to a stirred suspension of lithium aluminium hydride (25 g) in tetrahydrofuran (1000 ml). After 20 hours reflux, unreacted lithium aluminium hydride was destroyed by the addition of sodium sulfate decahydrate. The mixture was filtered, and the filtrate was evaporated _i_n vacuo. Distillation ii vacuo gave the title compound with boiling point 71-72°C/15 mmHg.
Preparation 3
2,5,5-Trimethyl-3-thiomorpholinnne
This compound was obtained from 2 , 2-dimethylaziridine and methyl-2-mercaptopropionate as described in Preparation
1. Melting point: 137 - 138°C.
Preparation 4 2,5 ,5-Trimethyl-thiomorpholine
This compound was prepared as described in Prepara- tion 2 by substituting 2 , 5 , 5-tri ethy1-3-thiomorpholinone for 5,5-dimethyl-3-thiomorpholinone. Boiling point: 76 - 77°C/15 mmHg.
Preparation • 5 2-(l-Butyl)-3-thiomorpholinone
Potassium hydroxide (56 g) was added to a suspension of cysteamine, hydrochloride (56.5 g) in absolute ethanol
(300 ml) followed by dropwise addition of ethyl 2-bromo- hexanoate (111.5 g). When the exothermic reaction ceased, the mixture was refluxed for 3 hours and filtered. Concen¬ tration of the filtrate .L_n vacuo gave the title compound as a viscous oil which was used in the next step without purification.
Preparation 6 2-(l-Butyl)-thiomorpholine, hydrochloride This compound was prepared as described in Prepara¬ tion 2 by substituting 2-( 1-butyl )-3-thiomorpholinone for 5,5-dimethyl-3-thiomorpholinone.
A solution of the crude 2-( 1-butyl ) -thiomorpholine in ether was treated with an excess of hydrogen chloride in ether to yield a crystalline hydrochloride with melting point 104°C. Microanalysis :
Calculated: C: 49.08 H: 9.27 N: 7.16 S: 16.38 Cl: 18.11 Found: . ' C: 49.12 H: 9".34 N: 7.09 S: 16.19 Cl: 18.00
Preparation 7 N-Formyl-thiomorpholine
Chloral (10 ml) was added dropwise to a solution of thiomorpholine (10 g) in tetrachloromethane (50 ml), and the resulting mixture was refluxed for 1 hour. Distil¬ lation i_π vacuo gave N-farmy1-thiomorpholine with boiling point 140°C/15 mmHg. When kept at room temperature, the pure product formed low melting crystals.
Preparation 8
By following the procedure described in Preparation 7 and substituting the appropriately substituted thiomorph¬ oline for thiomorpholine itself, the following compounds were prepared: N-Formyl-2-methyl-thiomorpholine: B.p. : 141-142°C/15 mmHg
N-Formyl-3-methyl-thiomorpholine: B.p. : 146-147°C/15 mmHg
N-Formyl-3,3-dimethyl-thiomorpholine: B.p.: 155-156°C/15mmHg N-Formyl-2,5,5-trimethyl-thiomorpholine: B.p. : 154-155°C/15 mmHg
N-Formyl-2-ethyl-thiomorpholine: B.p. : 75°C/1.5 mmHg
N-Formyl-2,2-dimethyl-thiomorpholine: B.p. : 75-76°C/l mmHg
N-Formyl-3-ethyl-thiomorpholine: B.p. : 145-146°C/15 mmHg
N-Formyl-2-(1-butyl)-thiomorpholine: B.p. : 160-162°C/15 mmHg N-Formyl-2-phenyl-thiomorpholine: B..p. : 148-150αC/l mmHg
Preparation 9 N-Formyl-2,6-dimethyl-thiomorpholine
Piperidine (10 ml) and 10 ml of a 40?ό solution of benzyltrimethylammoniumhydroxide in methanol were added to a solution of N-formyl-diallylamine (55 g) in methanol (200 ml). Hydrogen sulfide (50 g) was introduced into the resulting solution, and unreacted hydrogen sulfide was kept at reflux for 7 hours by means of a "cold finger". The mixture was left at room temperature for 48 hours, flushed with nitrogen, diluted with ether, and washed with water. The organic phase was dried, and the solvent evaporated JL--B. vacuo . Distillation of the residue gave the title com¬ pound with boiling point 145°C/15 mmHg.
Preparation 10 N-Formyl-3-ethyl-2-methyl-thiomorpholine
Cystea ine, hydrochloride (68.2 g, 0.6 mole) was added to an ice-cold stirred solution of sodium (27.6 g, 1.2 mole) in ethanol (1000 ml). -Bromo-diethyl ketone (99 g, 0.6 mole) was then added slowly in a nitrogen atmosphere while the temperature was kept below 25°C.
After stirring for 2 hours, the mixture as filtered, and the filtrate evaporated ij vacuo to leave an oil which was taken up in water (300 ml) and extracted with ether (2 x 500 ml). The organic phase was separated, dried and evaporated to give an oil which was distilled ijn vacuo . The distillate (b.p. 70°C/1 mmHg) was heated to 140°C with stirring, and formic acid (100 ml) was added at such a rate that the temperature was kept at 135-140°C without external heating. After standing overnight at room temperature, the stirred mixture was slowly treated with 40?ό potassium hydr¬ oxide (200 ml) and extracted with ether'(2 x 500 ml). The organic phase was dried and concentrated to about 500 ml. Chloral (80 ml) was added, and the mixture was refluxed for 1 hour, cooled and evaporated to leave an oil which was distilled jjτ_ vacuo to give the title compound with b.p.: 102 - 104°C/1 mmHg.
Preparation 11 By following the procedure described in Preparation
10 and substituting the appropriate α-bromo ketones for α-bromo-diethy1 ketone, the following compounds were pre¬ pared :
N-Formyl-2,3-dimethyl-thiomorpholine: B.p. : 88-90°C/l mmHg
N-Formyl-2-isopropyl-3-methyl-thiomorpholine: B.p. : 125-126°C/1 mmHg
N-Formyl-2-isobutyl-3-methyl-thiomorpholine: B.p. : 115-116°C/1 mmHg
N-Formy l - perhydro- l , 4-benz oth iaz i ne :
M . p . : 70- 71 ° C .
B.p. : 128-130°C/1 mmHg
N-Formyl-7-methyl-perhydro-l,4-benzothiazine: M.p.: 135-136°C
N-Formyl-3-isobutyl-thiomorpholine: B.p. : 110-114°C/1 mmHg
Preparation 12 By using the appropriate starting materials and fol¬ lowing the procedures described in Preparations 1,2 and 7, the following compounds were prepared.
N-Formyl-2-isobutyl-thiomorpholine: B.p. : 150-155°C/15 mmHg N-Formyl-2,5-dimethyl-thiomorpholine: B.p. : 142-143°C/15 mmHg
Preparation 13 By repeating the procedure of Preparation 10 and replacing α-bromo-diethyl ketone by the appropriate α-bromo ketones, the following compounds were prepared.
N-Formyl-3-(n-propyl) -thiomorpholine
N-Formyl-3-isopropyl-thiomorpholiπe B.p. : 95-96°C/l mmHg N-Formyl-3-phenyl-thiomorpholine
N-Formyl-2-ethyl-3-methyl-thiomorpholine
N-Formyl-3-(n-butyl) -thiomorpholine
N-Formyl-2-ethyl-3-propyl-thiomorpholine B.p. : 122-123°C/1 mmHg N-Formyl-2-isopropyl-3-isobutyl-thiomorpholine B.p. : 122-123°C/1 mmHg
N-Formyl-2,2-dimethyl-3-isopropyl-thiomorpholine B.p. : 116-117DC/1 mmHg
N-Formyl-3-cyclopropyl-thiomorpholine B.p. : 109-110°C/1 mmHg
N-Formyl-3-nonyl-thiomorpholine B.p. : 147-148°C/1 mmHg N-Formyl-3-tert-butyl-thiomorpholine B.p. : 113-114°C/1 mmHg
N-Formyl-2,2-dimethyl-3-phenyl-thiomorpholine
N-Formyl-5-methyl-2-phenyl-thiomorpholine
N-Formyl-3-isopentyl-thiomorpholine N-Formyl-3-cyclohexyl-thiomorpholine
N-Formyl-2-phenyl-3-benzyl-thiomorpholine
N-Formyl-2-pentyl-3-hexyl-thiomorpholine
Preparation 14 3-t&rt-Butyl-thiomorpholine
This compound was prepared as described in Prepara¬ tion 10 by using bromomethyl tert-butyl ketone instead of α-bromo-diethyl ketone and by omitting the treatment with chloral. The title compound was distilled in vacuo, b.p. : 73-74°C/l mmHg.
Preparation 15 (+)-3-tert-Butyl-thiomorpholine
3-tert-Buty1-thiomorpholine (159 g, racemic form des- cribed in Preparation 14) was added to a hot solution of (+)-tartaric acid (150 g) in water (100 ml). The mixture was left overnight and filtered. The crystalline salt
20 which showed [α.]n = +20° (c=l, H_0) was recrystallized repeatedly from water until [α], 2-.0 = +32° (c=l, H„0). The free base was liberated with an excess of 30 % potassium hydroxide and taken up in ether. The solution was dried and evaporated to leave the title compound as an oil with
[ ]p° = +36.1° (c=l, EtOH) .
Preparation 16 (-)-3-tert-Butyl-thiomorpholine
3-tert-Butyl-thiomorpholine - liberated from the combined filtrates obtained in Preparation 15 during the preparation of the tartrate - was treated with (-) tartaric acid in water. The resulting tartrate was recrystallized - until [ctlr 2j0 = -31.4° (c=l, H_0). The free base showed
[α]p° = -36.0° (c=l, EtOH).
Preparation 17
The compounds prepared in Preparations 15 and 16 were formylated with chloral as described in Preparation 7 to yield
(+)-N-formyl-3-tert-butylthiomorpholine [α]p° = +108° (c=l, EtOH) and
(-)-N-formyl-3-tert-butylt-hiomorpholine [α]p° = -107° (c=l, EtOH).
Preparation 18
By following the procedures described in Examples 15, 16 and 17 other substituted thiomorpholines may be resolved into the enantiomers and subsequently formylated to form e.g. (+)-N-formyl-3-isobutylthiomorpholine
(-)-N-formyl-3-isobutylthiomorpholine
Preparation 19 N-Formyl-tetrahydro-l,4-thiazepin-3-one To a solution of sodium (23 g) in absolute ethanol
(1 1) was added ethyl thioglycolate (60.1 g) and 3-bromoprop- ylamine, hydrobromide (109.5 g). After reflux for 12 hours, the mixture was cooled and filtered. The filtrate was evapo¬ rated in vacuo, and the residue was crystallized from ethanol to yield tetrahydro-1 ,4-thiazepin-3-one with m.p. 145-148°C. 60 g of this product was added in portions to a stirred suspension of lithium aluminium hydride (25 g) in tetra-
hydrofuran (2.5 1). The mixture was kept at 45-50°C for 2 hours followed by reflux for a further 2 hours. After cooling a mixture of water (62 ml) and tetrahydrofuran (250 ml) was added dropwise with stirring. Filtration and evaporation of the filtrate gave a residue which was dis¬ solved in ether (250 ml), dried over magnesium sulfate, filtered and treated dropwise with chloral (40 ml). After reflux for 1 hour the solvent was evaporated, and the residue distilled in vacuo to yield the title compound with b.p. 158-159°C/18 mmHg.
Preparation 20 N-Formyl-2-methyl-tetrahydro-l,4-thiazepin-3-one
This compound was prepared by following the proce- dure of Preparation 19, but substituting ethyl 2-mercapto- propionate for ethyl thiogiycolate . 2-Methy1-tetrahydro- -l,4-thiazεpin-3-one with m.p. 192-193°C was isolated as an intermediate. The title compound was a colourless oil with b.p. 104-105°C/1 mmHg.
Example ' 1 (4-Thiomorpholinylmethylene)-bisphosphonic acid
Oxalyl chloride (16.6 ml) was added dropwise at 0°C to a stirred solution of N-formyl-thiomorpholine (26.2 g) in methylene chloride (200 ml). The mixture was stirred at room temperature until the gas evolution ceased (about 5 hours later). Triethyl phosphite (66 ml) was then added during 1.5 hours at room temperature. Unreacted triethyl phosphite was removed i_n_ vacuo , and the residue was refluxed with 20 °a' hydrochloric acid (150 ml) for 3 hours. The mixture was evaporated to dryness in_ vacuo , and the residue was stirred with acetone. The crystalline product was filtered and recrystallized from water. M.p.: >250°C (dec). Microanalysis :
Calculated: C: 21.67 H: 4.73 N: 5.05 S: 11.57 Found:. C: 21.56 H: 4.77 N: 4.95 .S: 11.35 NMR (NaOD, TMS = 0.0 ppm as reference): S = 2.8-3.1 (lit, 4H); 3.21 (t, J=18 Hz, 1H) and 3.7-4.0 (m, 4H) ppm.
Example 2 By following the procedure described in Example 1 and substituting the appropriate N-formyl-derivatives de¬ scribed in Preparations 8, 9, 10, 11 and 12 for N-formyl- -thiomorpholine, the following compounds were prepared:
(2-Methyl-4-thiomorpholinylmethylene)-bisphosphonic acid M.p.: >250°C (dec).
NMR (NaOD, HD0 = 4.66 ppm as reference) : & - 1.20 (d, J=6.8 Hz, 3H) and 2.7-3.8 (m,8H) ppm. (2-(l-Butyl)-4-thiomorpholinylmethylene)-bisphosphonic acid M.p.: 226-227°C.
NMR (NaOD, HD0 = 4.66 ppm as reference): £> = 0.78 (t, 3H); 1.28 (bs, 6H) and 2.4-3.6 (m, 8H) ppm.
(2-Ethyl-4-thiomorpholinylmethylene)-bisphosphonic acid M.p.: 237-238°C.
NMR (NaOD, HD0 = 4.66 ppm as reference): ^ 0.85 (m, 3H); 1.40 (m, 2H) and 2.4-3.4 (m, 8H) ppm.
(3,3-Dimethyl-4-thiomorpholinylmethylene)-bisphosphonic acid
NMR (NaOD, HDO = 4.66 ppm as reference): 6 = 1.52 (bs, 6H);
2.91 (bs, 2H) and 2.8-4.0 (m, 5H) ppm. (2,5,5-Trimethyl-4-thiomorpholinylmethylene)-bisphosphonic acid
M.p.: 200°C (dec).
NMR (NaOD, HDO = 4.66 ppm as reference): 6 = 1.20 (d, J=7 Hz, 3H); 1.48 (s, 3H); 1.58 (s, 3H) and 2.6-4.0 (m, 6H) ppm, (2-Phenyl-4-thiomorpholinylmethylene)-bisphosphonic acid M.p.: 250°C (dec).
NMR (NaOD, HDO = 4.66 ppm as reference): 6 - 2.4-3.6 (m, 7H); 4.0 (m, 1H) and 7.25 (m, 5H) ppm.
(2,2-Dimethyl-4-thiomorpholinylmethylene)-bisphosphonic acid
M.p.: 246-247°C.
NMR (NaOD, HDO = 4.66 ppm as reference): 6 = 1.37 (s, 6H); 3.00 (bt, 2H); 3.41 (t, J=18.5 Hz, 1H); 3.61 (bs, 2H) and 3.75 (bt, 2H) ppm. (3-Methyl-4-thiomorpholinylmethylene)-bisphosphonic acid M.p.: 221-222°C.
NMR (NaOD, HDO = 4.66 ppm as reference): 6 - 1.46 (d, J=6.5 Hz, 3H); 2.4-3.2 (m, 4H) and 3.5-4.3 (m, 4H) ppm.
(3-Ethyl-4-thiomorpholinylmethylene)-bisphosphonic acid M.p.: 226-227°C.
NMR (NaOD, TMS = 0.0 ppm as reference): S = 1.01 (t, 3H); 2.00 (m, 2H); 2.9-3.2 (m, 4H); 3.5 (t, 1H) and 3.7-4.3 (m, 3H) ppm .
(2,6-Dimethyl-4-thiomorpholinylmethylene)-bisphosphonic acid
M.p.: 245°C (dec).
NMR (NaOD, TMS = 0.0 ppm as reference): 0 - 1.4 (m, 6H) and
3.1-4.0 (m, 7H) ppm.
(2,5-Dimethyl-4-thiomorpholinylmethylene)-bisphosphonic acid, monohydrate M.p.: 219-220°C.
NMR (NaOD, TMS = 0.0 ppm as reference): i = 1.4-1.8 (m, 6H), 3.2 (d, 2H) and 3-4.5 (m, 5H) ppm.
(2,3-Dimethyl-4-thiomorpho Iin-y'lme hylene)- bisphosphonic acid
M.p.: 200-202°C.
NMR (D O, HDO = 4.66 ppm as reference): 6 = 1.18 (m, 3H), 1.43 (m, 3H) and 2.5-4.3 (m, 7H) ppm.
(2-Isobutyl-4-thiomorphάlinylmethylene)-bisphosphonic acid M.p.: 238°C (dec).
NMR (NaOD, HDO = 4.66 ppm as reference): 6= 0.83 (d, 6H); 1.35 (t, 2H); 1.7 (m, IH) and 2.75-4.0 (m, 8H) ppm. (2-Isobutyl-3-methyl-4-thiomorpholinylmethylene)-bisphos¬ phonic acid, disodium salt
NMR (D O, TMS =.0.0 ppm as- reference): & = 0.93 (m, 6H); 1.1-2 (m, 6H) and 2.9-4.3 (m, 7H) ppm.
(3-Ethyl-2-methyl-4-thiomorpholinylmethylene)-bisphosphonic acid
NMR (NaOD, HDO = 4.66 ppm as reference): 6 - 0.83 (t, 3H), 1.17 (m, 3H); 1.8-2.1 (m, 2H) and 2.5-4.25 ( , 7H) ppm.
(2-Isopropyl-3-methyl-4-thiomorpholinylmethylene)-bisphos¬ phonic acid M.p.: 214-216°C.
NMR (NaOD, HDO = 4.66 ppm as reference): & - 0.95 (m, 6H); 1.47 (d, 3H); 1.55 (m,lH); 3.46 (t, J=16 Hz, IH) and 2.6-4.7 (m, 6H) ppm .
[(7-Methyl-perhydro-l,4-benzothiazin-4-yl)-methylene]-bis- phosphonic acid M.p.: 256-257°C.
NMR (NaOD, HDO = 4.66 ppm as reference): 8 = 0.80 (d, 3H), 0.9-2.0 (m, 6H), 2.2-2.5 (m, IH) and 2.6-4.3 (m, 7H) ppm.
[(Perhydro-l,4-benzothiazin-4-yl)-methylene]-bisphosphonic acid
M.p.: 257-258°C.
NMR (NaOD, HDO = 4.66 ppm as reference): <£ = 0.9-2.0 (m,
7H); 2.2-3.8 (m, 7H) and 4.15 (bd, IH) ppm. (3-Isobutyl-4-thiomorpholinylmethylene)-bisphosphonic acid M.p.: 237-238°C (dec).
NMR (NaOD, TMS = 0.0 ppm as reference): o = 0.97 (bm, 6H); 1.4-2.0 (m, 3H); 2.5-3.2 (m, 4H) and 3.3-4.0 (m, 4H) ppm.
Example 3
[l-(4-Thiomorpholiny1) -ethylidene]-bisphosphonic acid, bis-
-benzylamine salt
A mixture of N-acety1-thiomorpholine (14.5 g) and phosphorous acid (24.6 g) was heated at 100°C for 3 hours. Phosphorus trichloride (41.1 g) was added dropwise with stirring and after reflux for 3 hours, water (80 ml) was added slowly, and the mixture was kept at 100°C for 3 hours.
Filtration and evaporation of the filtrate ga.ve an oil which was taken up in ethanol. The title compound was precipitated by the addition of ether. The crude product was transformed into a bis-benzylamine salt with m.p. : 223-224°C.
NMR (D O, HDO = 4.66 ppm as reference): 6 = 1.51 (t, 0=13
Hz, 3H); 2.95 (t, 4H); 3.85 (m, 4H); 4.07 (s, 4H) and 7.36
(s , 10H) ppm .
Example 4 Tetrabenzyl (4-thiomorpholinylmethylene) -bisphosphonate sulf- oxide
Oxalyl chloride (0.85 ml) was added dropwise at -10°C to a stirred solution of N-formyl-thiomorpholine (1.31 g) in tetrahydrofuran (10 ml), arid the mixture was stirred at -10°C for 1 hour.
A solution of sodium dibenzylphosphite in tetrahydro- furan (20 ml) ^prepared from dibenzylphosphite (8.4 g) and 55?ό NaH (1.08 g)) was added, and after stirring for 1 hour the solvent was evaporated and the remaining oil distributed
between water and ethylene chloride. The organic phase was dried and evaporated to leave an oil which was purified by flash chromatography on silica gel (ether :acetone 90:10 as elαent) to yield tetrabenzyl (4-thiomorpholinylmethyl- ene)-bisphosphonate (1.27 g) which was taken up in alcohol- free chloroform (15 ml). This solution was cooled in ice and treated dropwise with a solution of 90% 3-chloroper- benzoic acid (0.38 g) in alcoholfree chloroform (5 ml). The ice bath was removed, and after stirring for a further 90 minutes the solvent was removed ijn vacuo , and the residue was purified by chromatography on silica gel to give the title compound as a colourless oil.
NMR (CDC1,, TMS = 0.0 ppm as reference): 6 = 2.62 (bt, 4H); 3.0 (b , 2H); 3.36 (t, J=25 Hz, IH); 3.60 (b , 2H); 5.04 (m, 8H) and 7.30 (s, 20H) ppm.
Example 5 (4-Thiomorpholinylmethylene) -bisphosphonic acid sulfoxide
To a solution of tetrabenzyl (4-thiomorpholinylmeth- ylene)-bisphosphonate sulfoxide (1 g) in ethyl acetate (15 ml) were added water (15 ml) and 10?ά palladium on carbon (1 g). The resulting mixture was shaken vigorously in a hydrogen atmosphere until the consumption of hydrogen ceased The catalyst was removed by filtration, and the aqueous phase was separated and freeze-dried to yield the title compound as an amorphous powder.
NMR (NaOD, HDO = 4.66 ppm as reference): 6 = 2.75 (t, J= 22.6 Hz, IH); 2.7-3.25 (m, 6H) and 3.3-3.7 (m, 2H) ppm.
Example 6 The procedure of Example 1 is repeated, except that N-formyl-thiomorpholine is replaced by the appropriate N- -formyl derivatives described in Preparation 13. This af¬ fords :
[3-(n-Propyl)-4-thiomorpholinylmethylene]-bisphosphonic acid
(3-Isopropyl-4-thiomorpholinylmethylene) -bisphosphonic acid M.p. : 240-241°C
(3-Phenyl-4-thiomorpholinylmethylene)-bisphosphonic acid M.p.: 257-258°C (d). (2-Ethyl-3-methyl-4-thiomorpholinylmethylene)-bisphosphonic acid
[3-(n-Butyl)-4-thiomorpholinylmethylene]-bisphosphonic acid
Example 7
(3-Isobutyl-4-thiomorpholinylmethylene)-bisphosphonic acid
A mixture of N-formyl-3-isobuty1-thiomorpholine (18.7 g) and phosphorous acid (16.4 g) was heated at 100°C for 2 hours. Phosphorus trichloride (30 ml) was added drop- wise with stirring, and after reflux for 3 hours water (180 ml) was added slowly. The mixture was refluxed for 1 hour and filtered. Evaporation of the filtrate gave a residue which was triturated wi'th ethanol to yield a cry¬ stalline compound which was isolated by filtration. M.p.: 237-238°C (dec).
Example 8 The procedure of Example 7 was repeated, except that N-formyl-3-isobuty1-thiomorpholiπe was replaced by the appropriate N-formyl-derivative described in Preparation 13, 17 and 18. In this way the following compounds were prepared
(3-Phenyl-4-thiomorpholinylmethylene)-bisphosphonic acid M.p.: 257°C (dec).
(2-Ethyl-3-propyl-4-thiomorpholinylmethylene)-bisphosphonic acid
M.p.: 213-215°C.
(3-Isopropyl-4-thiomorpholinylmethylene)-bisphosphonic acid M.p.: 240-241°C.
(2-Isopropyl-3-isobutyl-4-thiomorpholinylmethylene)-bis- phosphonic acid M.p. : 225°C.
(2,2-Dimethyl-3-isopropyl-4-thiomorpholinylmethylene)-bis- phosphonic acid M.p.: 202-205°C.
(2, 2-Dimethyl-3-phenyl-4-thiomorpholinylmethylene)-bis¬ phosphonic acid M.p.: 242°C. (3-Methyl-2-phenyl-4-thiomorpholinylmethylene)-bisphosphon¬ ic acid M.p.: 251°C. (dec.)
(3-Cyclopropyl-4-thiomorpholinylmethylene)-bisphosphonic acid M.p.: 221°C. (dec.)
(3-Nonyl-4-thiomorpholinylmethylene)-bisphosphonic acid M.p.: 197-200°C.
(3-Tert.butyl-4-thiomorpholinylmethylene)-bisphosphonic acid M.p.: 217°C (dec).
(+)-(3-Tert.butyl-4-thiomorpholinylmethylene)-bisphosphonic acid
M.p.: 216-217°C (dec).
[α]p° = + 33.4° (c=l, IN NaOH). (-)-( 3-Tert.butyl-4-thiomorpholinylmethylene)-bisphosphonic acid
M.p. : 216-217°C (dec. ). [α]p° = -33.8° (c=l, IN NaOH).
(3-Isopentyl-4-thiomorpholinylmethylene)-bisphosphonic acid
(3-Cyclohexyl-4-thiomorpholinylmethylene)-bisphosphonic acid
(+)-(3-1sobutyl-4-thiomorpholinylmethylene)-bisphosphonic acid
[α]p° = +54° (c=l, IN NaOH)
(-)-(3-Isobutyl-4-thiomorpholinylmethylene)-bisphosphonic acid o-]p° = -54.3° (c=T, IN NaOH)
(2-Phenyl-3-benzyl-4-thiomorpholinylmethylene)-bisphosphonic acid (2-pentyl-3-hexyl-4-thiomorpholinylmethylene)-bisphosphonic acid
Example 9 Disodium (4-thiomorpholinyImethylene)-bisphosphonate sulf- oxide, monohydrate
30?ό Aqueous hydrogen peroxide (11.1 ml) was added with stirring to a solution of ( -thiomorpholinylmethylene)- -bisphosphonic acid (27.7 g) in 5 M NaOH (40 ml). When the exothermic reaction had ceased the solvent was evapo- rated, and the residue was treated with ethanol and filtered to yield the title compound as colourless crystals. The NMR-spectrum was identical with that described in Example 5.
Example 10
By following the procedure described in Example 9 the following sulfoxides were prepared:
Disodium [3- (tert.butyl )-4-thiomorpholinylmethylene]-bis¬ phosphonate sulfoxide Disodium (3-isobutyl-4-thiomorpholinylmethylene)-bisphos¬ phonate sulfoxide
Disodium (3-cyclopropyl-4-thiomorpholinyImethylene)-bisphos¬ phonate sulfoxide
Example 11
By following the procedure of Example 1, but substi-
tuting the N-formyl-derivatives of Preparation 19 and 20 for N-formyl-thiomorpholine the following compounds were prepared :
(Tetrahydro-l,4-thiazepin-4-yl-methylene)-bisphosphonic acid
M.p.: 239-240°C.
(2-Methyl-tetrahydro-l,4-thiazepin-4-yl-methylene)-bis¬ phosphonic acid
M.p.: 241°C.
Example 12 Tetra-pivaloyloxymethyl (4-thiomorpholinylmethylene)-bis¬ phosphonate
A solution of (4-thiomorpholinylmethylene )-bisphos- phonic acid (2.8 g) in water (60 ml) was treated with four equivalents of aqueous te rabutylammonium hydroxide and freeze-dried. Remaining water was removed azeotropically with toluene. The resulting salt was suspended in tetra- hydrofuran (120 ml), and iodomethyl pivalate (9.4 ml) was added with stirring. After stirring for 1 hour at room temperature, the mixture was filtered, and the filtrate evaporated in vacuo. The residue was taken up in ethyl acetate and washed with aqueous sodium bicarbonate, dried and evaporated in vacuo. Chromatography on silica gel (eluent: petroleum ether - ethyl acetate 7:3) gave the pure title compound which crystallized on standing. M.p.: 86-88°C.
NMR (CDC13): & = 1.24 (s, 36H); 2.65 (m, 4H); 3.25 (m, 4H); 3.55 (t, J=26 Hz, IH) and 5.70 (m, 8H) ppm.
Example 13 Tetra-acetoxymetyl (4-thiomorpholinylmethylene)-bisphos- phonate
By following the procedure described in Example 12, but substituting iodomethyl acetate for iodomethyl pivalate, the title compound was obtained as a colourless
oil.
NMR (CDC13): 5 = 2.14 (s, 6H); 2.16 (s, 6H); 2.65 (m, 4H);
3.26 (m, 4H); 3.53 (t, J=26 Hz, IH) and 5.70 (m, 8H) ppm.
Example 14 Di-pivaloyloxymetyl (4-thiomorpholinyImethylene) -bisphos¬ phonate disodium salt
A solution of tetra-pivaloyloxymethyl (4-thiomorph- olinyImethylene )-bisphosphonate (0.37 g) and sodium iodide (0.22 g) in acetone (5 ml) was refluxed for 90 minutes, cooled and filtered to yield the title compound as colour¬ less crystals. NMR: (D20): & = 1.16 (s, 18H); 2.65 (m, 4H); 3.05 (t, IH);
3.18 (m, 4H) and 5.52 (m, 4H) ppm
Example 15 Di-acetoxymethyl (4-thiomorpholinylmethylene) -bisphos¬ phonate disodium salt
This compound was prepared from tetra-acetoxymεthy1 ( -thiomorpholinylmethylεne )-bisphosphonate by following the procedure of Example 14.
NMR (D20): 6 - 2.09 (s, 6H); 2.65 (m, 4H); 3.10 (t, IH); 3.25 (m, 4H) and 5.50 (m, 4H) ppm.
Claims
WHAT WE CLAIM IS:
A compound of the formula I
in which R--R-, can be the same or different and stand for hydrogen, a straight or branched alip atie or alicyclic C.-C,0 hydrocarbon radical, an aryl or an aryl-C, -C.-alkyl radical; n is zero or one, and m is zero, one or two; and salts and in vivo hydrolyzable esters thereof.
2. A compound according to claim 1, in which R„ and - R. in formula I when taken together form a saturated ali¬ phatic ' - , 6- or 7-membered ring which may be substituted with one or more C,-C, -alkyl radicals.
3. A compound according to claim 1, in which R,-R- , being the same or different, stands for hydrogen, C.-C,-- -alkyl or phenyl.
4. A salt according to claim 1, which is a salt of a compound of formula I with a pharmaceutically acceptable non-toxic base, such salt being selected from the group consisting of alkali metal salts, alkaline earth metal salts, or salts with ammonia or suitable non-toxic amines, such as lower alkylamines, lower alkanola ines , procaine, cycloalkylamines, benzylamines, and heterocyclic amines.
5. An ester of a compound of formula I according to claim 1 selectεd from the group consisting of alkanoyloxy- methyl of three to six carbon atoms, 1-(alkanoyloxy )ethyl of four to seven carbon atoms, 1-methyl-l- ( alkanoyloxy )- εthyl of five to eight carbon atoms, alkoxycarbon loxy- methyl of three to six carbon atoms, 1-(alkoxycarbonyloxy )- εthyl of four to seven carbon atoms, 1-methyl-l-(alkoxycarb¬ onyloxy )εthyl of fivε to eight carbon atoms, 3-phthalidy1 , 4-crotonolactony1, y-butyrolacton-4-y1 , (2-oxo-l , 3-dioxolen- -4-yl)methyl, (5-methyl-2-oxo-l,3-dioxolεn-4°-yl)methyl,
(5-phenyl-2-oxo-l,3-dioxolen-4-yl)methyl, dialkylaminoalkyl, acεtonyl, and mεthoxymεthyl .
6. A compound of formula I according to claim 1, se- lεctεd from the group consisting of
(4-thiomorpholinyImethylene )-bisphosphonic acid and its salts and esters, and
( 3-isobuty1-4-thiomorpholinylmethylene )-bisphosphonic acid in racemic form or in the form of the singlε enantiomers, and salts and estεrs thereof, and
(3-tert-butyl-4-thiomorpholinylmεthylene)-bisphosphonic acid in racemic form or in the form of the single enantio¬ mers, and salts and esters. thereof, and
(2-methyl-4-thiomorpholinylmethylene)-bisphosphonic acid in racemic form or in the form of the single enantiomers, and salts and esters thereof.
7. A method for producing a compound of formula I of claim 1, in which a compound of formula II where R--R-- and m have the meanings defined in claim 1, is transf'ormed into an acid amide chloride which is reacted with a trialkylphosphite to form a compound of formula
IV
where R,-R-- and m havε the meanings definεd in claim 1, and R•, ~ is a C.-C. -alkyl radical or a bεnzyl or a substi- tutεd benzyl radical, whereafter the compound of formula IV thus produced is hydrolyzed or hydrogenolyzed to form thε desired compound of formula I (n=0), or the compound of formula IV is optionally oxidized to form a compound in which n=l, followed by a hydrolysis or hydrogenolysis as above to form the desirεd compound of formula I (n=l); thε final compound of formula I bεing recovered as such or as a salt or ester as. defined in claim 1.
8. A method for producing a compound of formula I of claim 1, in which a compound of formula II, where R,-R,- and m have the mεanings dεfinεd in claim 1, is heated with a mixture of phosphorous acid and phosphorus trichloride or phosphorus oxychloride followed by a hydrolysis to form the desired compound of formula I (n=0) optionally followed by an oxidation to form a compound of formula I (n=l), the final compound of formula I being recovered as such or as a salt or ester as defined in claim 1.
9. A pharmaceutical composition, containing an effεctivε amount of onε or more of the compounds of claim 1, together with pharmaceutically acceptablε, non-toxic carriεrs and/or auxiliary agεnts.
10. A method for the treatmεnt of a patiεnt suffεring from ostεoporosis , rhεumatoid arthritis or othεr arthritic disordεr, athεrosclεrosis, hypεrcalcεmia due to malignancies or primary hyperparathyroidism, Pagets diseasε, or othεr condition with an abnormal calcium balancε, in which a composition according to claim 9 is administεrεd to the patient in need of treatment.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE8787900075T DE3670639D1 (en) | 1985-12-12 | 1986-12-10 | NEW BIPHOSPHONIC BODIES, THEIR PRODUCTION AND PREPARATION OF MEDICINAL PRODUCTS. |
DK406987A DK169678B1 (en) | 1985-12-12 | 1987-08-05 | New Bisphosphonic Acid Derivatives, Pharmaceutical Preparations Containing These, and Their Preparation and Use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8530603 | 1985-12-12 | ||
GB858530603A GB8530603D0 (en) | 1985-12-12 | 1985-12-12 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1987003598A1 true WO1987003598A1 (en) | 1987-06-18 |
Family
ID=10589647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1986/000132 WO1987003598A1 (en) | 1985-12-12 | 1986-12-10 | Novel bisphosphonic derivatives, a method for their production and a pharmaceutical composition |
Country Status (8)
Country | Link |
---|---|
US (1) | US4870063A (en) |
EP (1) | EP0248854B1 (en) |
JP (1) | JPS63501956A (en) |
CA (1) | CA1287350C (en) |
DE (1) | DE3670639D1 (en) |
DK (1) | DK169678B1 (en) |
GB (1) | GB8530603D0 (en) |
WO (1) | WO1987003598A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0416689A2 (en) * | 1989-09-06 | 1991-03-13 | Merck & Co. Inc. | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors |
WO1992011269A1 (en) * | 1990-12-20 | 1992-07-09 | Leiras Oy | Novel methylenebisphosphonic acid derivatives |
EP0498424A1 (en) * | 1991-02-07 | 1992-08-12 | Kaken Pharmaceutical Co., Ltd. | Bisphosphonic acid derivatives and bone resorption inhibitors containing them |
EP0513760A2 (en) * | 1991-05-13 | 1992-11-19 | E.R. SQUIBB & SONS, INC. | Use of biphosphonate squalene synthetase inhibitors in pharmaceutical compositions useful in lowering cholesterol |
US5227506A (en) * | 1989-09-06 | 1993-07-13 | Merck & Co., Inc. | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors |
FR2703590A1 (en) * | 1993-04-05 | 1994-10-14 | Sanofi Elf | Use of bisphosphonic acid derivatives for the preparation of medicaments for promoting bone repair. |
US5574024A (en) * | 1987-07-06 | 1996-11-12 | Ebetino; Frank H. | Methylene phosphonoalkylphosphinates, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
US6692764B2 (en) * | 1994-04-29 | 2004-02-17 | Merck & Co., Inc. | Wet granulation formulation for bisphosphonic acids |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
US6376476B1 (en) * | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
AU1525700A (en) | 1998-11-19 | 2000-06-05 | Board Of Trustees Of The University Of Arkansas, The | Increasing bone strength with selected bisphosphonates |
US7041309B2 (en) * | 2002-06-13 | 2006-05-09 | Neuropro Technologies, Inc. | Spinal fusion using an HMG-CoA reductase inhibitor |
WO2005090370A1 (en) | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
EP2842559A3 (en) | 2005-04-08 | 2015-03-18 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
EP1868628B1 (en) | 2005-04-08 | 2014-06-11 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
EP2254582B1 (en) * | 2008-01-25 | 2016-01-20 | Chimerix, Inc. | Methods of treating viral infections |
WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
EP2462152A4 (en) | 2009-08-03 | 2013-02-13 | Chimerix Inc | Composition and methods of treating viral infections and viral induced tumors |
US9006218B2 (en) | 2010-02-12 | 2015-04-14 | Chimerix Inc. | Nucleoside phosphonate salts |
EP2563367A4 (en) | 2010-04-26 | 2013-12-04 | Chimerix Inc | Methods of treating retroviral infections and related dosage regimes |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3232998A1 (en) * | 1982-09-04 | 1984-03-08 | Henkel KGaA, 4000 Düsseldorf | Diphosphonic acids |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH9776A (en) * | 1967-12-11 | 1976-03-17 | M Francis | Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue and method of use |
JPS5095227A (en) * | 1973-12-26 | 1975-07-29 | ||
US4264768A (en) * | 1978-08-09 | 1981-04-28 | Petrolite Corporation | Di-quaternary ammonium salts of α-1,4-thiazine alkanephosphonic acids |
US4311663A (en) * | 1978-08-09 | 1982-01-19 | Petrolite Corporation | α-1,4-Thiazine alkanephosphonic acids as corrosion inhibitors |
DE3225469A1 (en) * | 1982-07-05 | 1984-01-05 | Schering AG, 1000 Berlin und 4709 Bergkamen | DIPHOSPHONIC ACID DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
-
1985
- 1985-12-12 GB GB858530603A patent/GB8530603D0/en active Pending
-
1986
- 1986-12-10 US US07/090,980 patent/US4870063A/en not_active Expired - Fee Related
- 1986-12-10 WO PCT/DK1986/000132 patent/WO1987003598A1/en active IP Right Grant
- 1986-12-10 JP JP62500254A patent/JPS63501956A/en active Pending
- 1986-12-10 EP EP87900075A patent/EP0248854B1/en not_active Expired - Lifetime
- 1986-12-10 DE DE8787900075T patent/DE3670639D1/en not_active Expired - Fee Related
- 1986-12-11 CA CA000525118A patent/CA1287350C/en not_active Expired - Fee Related
-
1987
- 1987-08-05 DK DK406987A patent/DK169678B1/en active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3232998A1 (en) * | 1982-09-04 | 1984-03-08 | Henkel KGaA, 4000 Düsseldorf | Diphosphonic acids |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 83 (1975), Abstract No. 172 652u, Vitam. D Probl. Relat. Uremic Bone Dis., PRoc. Workshop, 2nd 1974 (Pub. 1975), 91-95. * |
CHEMICAL ABSTRACTS, Vol. 84 (1976), Abstract No. 54 233f, Dtsch. Gesundheitswes. 1975, 30(48), 2291-3. * |
CHEMICAL ABSTRACTS, Vol. 93 (1980), Abstract No. 231 891c, Stomatol. DDR 1980, 30(3), 169-175. * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5574024A (en) * | 1987-07-06 | 1996-11-12 | Ebetino; Frank H. | Methylene phosphonoalkylphosphinates, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
EP0416689A2 (en) * | 1989-09-06 | 1991-03-13 | Merck & Co. Inc. | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors |
EP0416689A3 (en) * | 1989-09-06 | 1991-06-26 | Merck & Co. Inc. | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors |
US5227506A (en) * | 1989-09-06 | 1993-07-13 | Merck & Co., Inc. | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors |
WO1992011269A1 (en) * | 1990-12-20 | 1992-07-09 | Leiras Oy | Novel methylenebisphosphonic acid derivatives |
EP0498424A1 (en) * | 1991-02-07 | 1992-08-12 | Kaken Pharmaceutical Co., Ltd. | Bisphosphonic acid derivatives and bone resorption inhibitors containing them |
US5350743A (en) * | 1991-02-07 | 1994-09-27 | Kaken Pharmaceutical Co., Ltd. | Bisphosphonic acid derivatives, as bone resorption inhibitors |
EP0513760A2 (en) * | 1991-05-13 | 1992-11-19 | E.R. SQUIBB & SONS, INC. | Use of biphosphonate squalene synthetase inhibitors in pharmaceutical compositions useful in lowering cholesterol |
EP0513760A3 (en) * | 1991-05-13 | 1992-12-23 | E.R. Squibb & Sons, Inc. | Use of biphosphonate squalene synthetase inhibitors in pharmaceutical compositions useful in lowering cholesterol |
FR2703590A1 (en) * | 1993-04-05 | 1994-10-14 | Sanofi Elf | Use of bisphosphonic acid derivatives for the preparation of medicaments for promoting bone repair. |
US5488041A (en) * | 1993-04-05 | 1996-01-30 | Sanofi | Method of promoting bone repair using tiludronic disodium salt |
US6692764B2 (en) * | 1994-04-29 | 2004-02-17 | Merck & Co., Inc. | Wet granulation formulation for bisphosphonic acids |
Also Published As
Publication number | Publication date |
---|---|
JPS63501956A (en) | 1988-08-04 |
EP0248854B1 (en) | 1990-04-25 |
DK169678B1 (en) | 1995-01-09 |
CA1287350C (en) | 1991-08-06 |
DE3670639D1 (en) | 1990-05-31 |
US4870063A (en) | 1989-09-26 |
DK406987D0 (en) | 1987-08-05 |
DK406987A (en) | 1987-08-05 |
GB8530603D0 (en) | 1986-01-22 |
EP0248854A1 (en) | 1987-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1987003598A1 (en) | Novel bisphosphonic derivatives, a method for their production and a pharmaceutical composition | |
US4732998A (en) | Bisphosphonic acids and esters | |
EP0409881B1 (en) | N-heterocyclic propylidene-1,1-bisphosphonic acids, their production and a pharmaceutical composition | |
JP4359150B2 (en) | Phosphate prodrug of fluorooxindole | |
JPS5942395A (en) | Antiinflammatory product derived from methylene-diphosphonic acid | |
AU657018B2 (en) | Guanidinoalkyl-1, 1-bisphosphonic acid derivatives, process for their preparation and their use | |
CN1058718C (en) | Optically active benzothiepin derivative, its preparation and use | |
JPH05239075A (en) | Phosphorus-containing isoprenoid derivative | |
US6903080B2 (en) | Disease treatment with novel phospholipid derivatives | |
EP0531253B1 (en) | N-substituted aminomethanediphosphonic acids | |
US5457094A (en) | Heterocyclic amidines useful for treating diseases associated with calcium metabolism | |
IL93960A (en) | Unsaturated aminodicarboxylic phosphoric acid derivatives, their preparation and pharmaceutical compositions containing them | |
IE903452A1 (en) | Phosphonic acid, a method for its manufacture, and its use as an active ingredient in medicines | |
DK169677B1 (en) | New n-heterocyclic propylidene-1,1-bis:phosphonic acids - useful as drugs influencing calcium metabolism for treating arthritic disorders, atherosclerosis etc. | |
JP2926168B2 (en) | Sulfur-containing compounds | |
CS489986A2 (en) | Method of pyridazo-/1,2-a//1,2/diazepine's new derivatives production | |
CN1086218A (en) | Anti-inflammatory agent phosphine acyl acetic acid ester and acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): DK JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BE DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1987900075 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1987900075 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1987900075 Country of ref document: EP |